Participate in the LELANTOS I Duchenne muscular dystrophy study

Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle degeneration and weakness affecting the whole body.

The LELANTOS I study is testing an investigational drug in patients with Duchenne muscular dystrophy who are unable to walk without braces or assistive devices to see if the drug can potentially maintain or improve the muscle strength of upper extremities and stabilize respiratory and heart functions.

Answer the following questions to see if you or your loved one is eligible for the study.

Check eligibility

Study details

Eligibility requirements

Participants must:

  • be male at least 12 years old
  • be on a stable dose of corticosteroids for at least 6 months
  • be diagnosed with Duchenne muscular dystrophy

Participants must not:

  • be able to walk
  • have taken pamrevlumab in the past
  • have severe uncontrolled heart failure, or renal dysfunction

If you would like to speak to someone regarding this trial, first check to see if you are initially eligible through the prescreener above. If it seems that you are eligible to take part, you will be contacted by phone so we can ask you additional questions to confirm your eligibility, and you will be able to ask any questions you may have about this clinical trial. If you are not eligible based on your responses to the prescreener, you can always contact us at patientsupport@antidote.me to discuss further.